|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistic, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tang Y, Wang WY, Zheng K, Jiang L, Zou Y,
Su XY, Chen J, Zhang WY and Liu WP: EGFR mutations in non-small
cell lung cancer: An audit from West China Hospital. Expert Rev Mol
Diagn. 16:915–919. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Minna JD, Fong K, Zöchbauer-Müller S and
Gazdar AF: Molecular pathogenesis of lung cancer and potential
translational applications. Cancer J. 8(Suppl 1): S41–S46.
2002.PubMed/NCBI
|
|
6
|
Villaflor V, Won B, Nagy R, Banks K,
Lanman RB, Talasaz A and Salgia R: Biopsy-free circulating tumor
DNA assay identifies actionable mutations in lung cancer.
Oncotarget. 7:66880–66890. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: Receptor heterodimerization in
development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Charpidou A, Blatza D, Anagnostou V and
Syrigos KN: Review. EGFR mutations in non-small cell lung
cancer-clinical implications. In vivo. 22:529–536. 2008.
|
|
9
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han JY, Park K, Kim SW, Lee DH, Kim HY,
Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, et al: First-SIGNAL:
First-line single-agent iressa versus gemcitabine and cisplatin
trial in never-smokers with adenocarcinoma of the lung. J Clin
Oncol. 30:1122–1128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang CC, Chao KH, Chen YL, Chang JG and Wu
SM: Capillary electrophoretic genotyping of epidermal growth factor
receptor for pharmacogenomic assay of lung cancer therapy. J
Chromatogra A. 1256:276–279. 2012. View Article : Google Scholar
|
|
13
|
Liu W, Smith DI, Rechtzigel KJ, Thibodeau
SN and James CD: Denaturing high performance liquid chromatography
(DHPLC) used in the detection of germline and somatic mutations.
Nucleic Acids Res. 26:1396–1400. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Do H, Krypuy M, Mitchell PL, Fox SB and
Dobrovic A: High resolution melting analysis for rapid and
sensitive EGFR and KRAS mutation detection in formalin fixed
paraffin embedded biopsies. BMC Cancer. 8:1422008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tuononen K, Maki-Nevala S, Sarhadi VK,
Wirtanen A, Rönty M, Salmenkivi K, Andrews JM, Telaranta-Keerie AI,
Hannula S, Lagström S, et al: Comparison of targeted
next-generation sequencing (NGS) and real-time PCR in the detection
of EGFR, KRAS and BRAF mutations on formalin-fixed,
paraffin-embedded tumor material of non-small cell lung
carcinoma-superiority of NGS. Genes Chromosomes Cancer. 52:503–511.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marchetti A, Martella C, Felicioni L,
Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli
F, Mezzetti A, et al: EGFR mutations in non-small-cell lung cancer:
Analysis of a large series of cases and development of a rapid and
sensitive method for diagnostic screening with potential
implications on pharmacologic treatment. J Clin Oncol. 23:857–865.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chu H, Zhong C, Xue G, Liang X, Wang J,
Liu Y, Zhao S, Zhou Q and Bi J: Direct sequencing and amplification
refractory mutation system for epidermal growth factor receptor
mutations in patients with non-small cell lung cancer. Oncol Rep.
30:2311–2315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Watanabe S, Minegishi Y, Yoshizawa H,
Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma
A, et al: Effectiveness of gefitinib against non-small-cell lung
cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac
Oncol. 9:189–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Liu B, Li XY, Li JJ, Qin HF, Tang
CH, Guo WF, Hu HX, Li S, Chen CJ, et al: A comparison of ARMS and
direct sequencing for EGFR mutation analysis and tyrosine kinase
inhibitors treatment prediction in body fluid samples of
non-small-cell lung cancer patients. J Exp Clin Cancer Res.
30:1112011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ueno T, Toyooka S, Suda K, Soh J, Yatabe
Y, Miyoshi S, Matsuo K and Mitsudomi T: Impact of age on epidermal
growth factor receptor mutation in lung cancer. Lung cancer.
78:207–211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang R, Zhang Y, Pan Y, Li Y, Hu H, Cai D,
Li H, Ye T, Luo X, Zhang Y, et al: Comprehensive investigation of
oncogenic driver mutations in Chinese non-small cell lung cancer
patients. Oncotarget. 6:34300–34308. 2015.PubMed/NCBI
|
|
25
|
Chen ZY, Zhong WZ, Zhang XC, Li Y, Hu H,
Cai D, Li H, Ye T, Luo X, Zhang Y, et al: EGFR mutation
heterogeneity and the mixed response to EGFR tyrosine kinase
inhibitors of lung adenocarcinomas. Oncologist. 17:978–985. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
International Early Lung Cancer Action
Program I; Henschke CI, Yip R and Miettinen OS: Women's
susceptibility to tobacco carcinogens and survival after diagnosis
of lung cancer. JAMA. 296:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bain C, Feskanich D, Speizer FE, Thun M,
Hertzmark E, Rosner BA and Colditz GA: Lung cancer rates in men and
women with comparable histories of smoking. J Natl Cancer Inst.
96:826–834. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chan-Yeung M and Dimich-Ward H:
Respiratory health effects of exposure to environmental tobacco
smoke. Respirology. 8:131–139. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Greenhalgh J, Dwan K, Boland A, Bates V,
Vecchio F, Dundar Y, Jain P and Green JA: First-line treatment of
advanced epidermal growth factor receptor (EGFR) mutation positive
non-squamous non-small cell lung cancer. Cochrane Database Syst
Rev. 25:CD0103832016.
|
|
30
|
Jida M, Toyooka S, Mitsudomi T, Takano T,
Matsuo K, Hotta K, Tsukuda K, Kubo T, Yamamoto H, Yamane M, et al:
Usefulness of cumulative smoking dose for identifying the EGFR
mutation and patients with non-small-cell lung cancer for gefitinib
treatment. Cancer Sci. 100:1931–1934. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Midha A, Dearden S and McCormack R: EGFR
mutation incidence in non-small-cell lung cancer of adenocarcinoma
histology: A systematic review and global map by ethnicity
(mutMapII). Am J Cancer Res. 5:2892–2911. 2015.PubMed/NCBI
|
|
32
|
Chen YM, Lai CH, Rau KM, Huang CH, Chang
HC, Chao TY, Tseng CC, Fang WF, Chen YC, Chung YH, et al: Advanced
non-Small cell lung cancer patients at the extremes of age in the
era of epidermal growth factor receptor tyrosine kinase inhibitors.
Lung cancer. 98:99–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Filosso PL, Ruffini E, Asioli S, Giobbe R,
Macri L, Bruna MC, Sandri A and Oliaro A: Adenosquamous lung
carcinomas: A histologic subtype with poor prognosis. Lung Cancer.
74:25–29. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gawrychowski J, Brulinski K, Malinowski E
and Papla B: Prognosis and survival after radical resection of
primary adenosquamous lung carcinoma. Eur J Cardiothorac Surg.
27:686–692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Riquet M, Perrotin C, Lang-Lazdunski L,
Hubsch JP, Dujon A, Manac'h D, Le Pimpec Barthes F and Briere J: Do
patients with adenosquamous carcinoma of the lung need a more
aggressive approach? J Thorac Cardiovasc Surg. 122:618–619. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li J, Wang L, Mamon H, Kulke MH, Berbeco R
and Makrigiorgos GM: Replacing PCR with COLD-PCR enriches variant
DNA sequences and redefines the sensitivity of genetic testing.
Nature medicine. 14:579–584. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ellison G, Donald E, McWalter G, Knight L,
Fletcher L, Sherwood J, Cantarini M, Orr M and Speake G: A
comparison of ARMS and DNA sequencing for mutation analysis in
clinical biopsy samples. J Exp Clin Cancer Res. 29:1322010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li C, Wu J, Wang Z and Feng J: A
comparison of direct sequencing and ARMS assay performance in EGFR
mutation analysis of non-small cell lung cancer patients. Zhongguo
Fei Ai Za Zhi. 17:606–611. 2014.(In Chinese). PubMed/NCBI
|
|
39
|
Jiang J, Wang C, Yu X, Sheng D, Zuo C, Ren
M, Wu Y, Shen J, Jin M and Xu S: PCR-sequencing is a complementary
method to amplification refractory mutation system for EGFR gene
mutation analysis in FFPE samples. Exp Mol Pathol. 99:581–589.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
von Ahlfen S, Missel A, Bendrat K and
Schlumpberger M: Determinants of RNA quality from FFPE samples.
PLoS One. 2:e12612007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hata A, Katakami N, Yoshioka H, Takeshita
J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, et al:
Rebiopsy of non-small cell lung cancer patients with acquired
resistance to epidermal growth factor receptor-tyrosine kinase
inhibitor: Comparison between T790M mutation-positive and
mutation-negative populations. Cancer. 119:4325–4332. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu VW, Upadhyay D, Schrock AB, Gowen K,
Ali SM and Ou SH: TPD52L1-ROS1, a new ROS1 fusion variant in lung
adenosquamous cell carcinoma identified by comprehensive genomic
profiling. Lung cancer. 97:48–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
